AI Companies Use Virtual Drug Trials to Enhance Human Study Success

This report highlights the use of AI-driven virtual drug trials aimed at improving the success rates of human clinical studies. The context includes Novartis' experimental drug del-desiran for muscular dystrophy, which recently failed a late-stage trial, leading to significant financial losses for the company. The development underscores the potential impact of AI in drug development amid challenges faced by traditional trials.

Originally published by gnews